Lnc-TMEM132D-AS1 as a potential therapeutic target for acquired resistance to osimertinib in non-small-cell lung cancer
Molecular Omics · 27.03.2023 · 19 (3) · 238-251
DOI: 10.1039/d2mo00261b ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Omics, online erschienen am 21.12.2022. Verfasst von Nan Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Life Sciences, Chongqing Medical University, Chongqing, China. lxwu@cqmu.edu.cn. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, RNA, Long Noncoding. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing, Chongqing Medical University.
Abstract (Originalsprache)
Acquired resistance is a major obstacle to the therapeutic efficacy of osimertinib in non-small-cell lung cancer (NSCLC). Current knowledge about the role of long non-coding RNAs (lncRNAs) in this phenomenon is insufficient. In this study, we screened the differentially expressed lncRNAs between osimertinib-sensitive and -resistant NSCLC cell lines, and determined that lnc-TMEM132D-AS1 was significantly upregulated in osimertinib-resistant NSCLC cells, as well as in the plasma of osimertinib-resistant NSCLC patients. Lnc-TMEM132D-AS1 markedly decreased the osimertinib sensitivity of NSCLC cells. After osimertinib exposure, it increased the cell proliferation and colony formation, decreased the cell apoptosis, and induced M2/G-phase cell cycle arrest. After identifying its cytoplasmic localization, a functional lnc-TMEM132D-AS1-miRNA-mRNA interaction network and a protein–protein interaction (PPI) network were constructed to analyze its putative target genes and biological functions. Lnc-TMEM132D-AS1 could directly bind to miR-766-5p and lead to the upregulation of ectonucleoside triphosphate diphosphohydrolase-1 (ENTPD1), resulting in an increase in cell proliferation. Moreover, upregulated ENTPD1 was also associated with enhanced tumor infiltration of immunosuppressive cells and poor prognosis in NSCLC patients. In summary, lnc-TMEM132D-AS1 plays a crucial role in osimertinib resistance. It may serve as a prognostic biomarker and a potential therapeutic target for acquired resistance to osimertinib in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Life Sciences, Chongqing Medical University, Chongqing, China. lxwu@cqmu.edu.cn.
- Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Hunan Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha, 410219, China.
- Academician Workstation, Changsha Medical University, Changsha, 410219, China.
- Molecular Medicine Diagnostic and Testing Center, Chongqing Medical University, Chongqing, China.
ORCID-Profile: Lanxiang Wu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
- Chongqing Medical University
- Science and Technology Planning Project of Yuzhong District of Chongqing City
- Chongqing Municipal Education Commission Foundation
Zitieren
APA
Wang, N., Zhao, Q., Huang, Y., Wen, C., Li, Y., Bao, M., & Wu, L. (2023). Lnc-TMEM132D-AS1 as a potential therapeutic target for acquired resistance to osimertinib in non-small-cell lung cancer. Molecular Omics, 19(3), 238-251. https://doi.org/10.1039/d2mo00261b
Vancouver
Wang N, Zhao Q, Huang Y, Wen C, Li Y, Bao M, et al. Lnc-TMEM132D-AS1 as a potential therapeutic target for acquired resistance to osimertinib in non-small-cell lung cancer. Molecular Omics. 2023;19(3):238-251. doi:10.1039/d2mo00261b
BibTeX
@article{Wang2023,
author = {Wang, Nan and Zhao, Qilin and Huang, Yutang and Wen, Chunjie and Li, Yaji and Bao, Meihua and Wu, Lanxiang},
title = {Lnc-TMEM132D-AS1 as a potential therapeutic target for acquired resistance to osimertinib in non-small-cell lung cancer},
journal = {Molecular Omics},
year = {2023},
volume = {19},
number = {3},
pages = {238--251},
doi = {10.1039/d2mo00261b}
}
EUVIMED